Form 144 Filer Information UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

Form 144

144: Issuer Information

Name of Issuer
BeiGene, Ltd.
SEC File Number
001-37686
Address of Issuer
94 Solaris Avenue, Camana Bay
Grand Cayman
Cayman Islands
CAYMAN ISLANDS
KY1 1108
Phone
345-949-4123
Name of Person for Whose Account the Securities are To Be Sold
Baker Brothers Life Sciences, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer
  1. Affiliate

144: Securities Information


RecordTitle of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
#1American Depositary Shares
J.P. Morgan
Securities LLC
383 Madison Avenue
New York
NEW YORK
10179
950,907$178,074,395.0266,842,97012/09/2024
NASDAQ

144: Securities To Be Sold

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

RecordTitle of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
#1American Depositary Shares08/02/2018See Remark 2Underwriter402,45309/05/2018Cash
#2American Depositary Shares01/18/2018See Remark 3Underwriter548,45401/22/2018Cash


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
(1) Baker Brothers Life Sciences, L.P. is affiliated with 667, L.P. Baker Bros. Advisors LP is the investment adviser to 667, L.P. and Baker Brothers Life Sciences, L.P. 667, L.P. is filing separately for the sale of 86,110 American Depositary Shares ("ADS") of BeiGene, Ltd (the "Issuer"), which along with the reported sales in this form by Baker Brothers Life Sciences, L.P. totals 1,037,017 ADS. Each ADS represents 13 Ordinary Shares of the Issuer. The outstanding shares number noted above represents outstanding ADS. All amounts above are expressed in ADS. (2) Purchase of Ordinary Shares in Issuer's HKEX IPO later converted to ADS. (3) Purchase of ADS in underwritten public offering.
Date of Notice
12/09/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature
By: BAKER BROS. ADVISORS LP, mgmt company and IA to Baker Brothers Life Sciences, L.P., /s/ Scott L. Lessing, President

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)